BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy of Medical Sciences, presented Phase 1b/2a results in a…
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), supporting the potential…
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 studyData highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth…
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cellsAmong patients with measurable disease in…
SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients…
The article outlines how first sessions build understanding, set goals, and support a comfortable start to therapy.IDAHO FALLS, Idaho, Oct. 24, 2026 /PRNewswire/ -- What should you expect during your first therapy session? HelloNation published an article that answers this…
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levelsClinical activity with Sofe-M was maintained even in patients with prior PARP…
SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in…
CHONGQING, China, Oct. 21, 2026 /PRNewswire/ -- A news report from iChongqing. The 2026 World Science and Technology Development Forum opened in Chongqing on October 21, bringing together around 800 participants, including experts and scholars, to explore how automotive technology,…
The financing round, led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, an Icelandic venture capital fund managed by AxUM Securities, was increased to US$21.5 million following strong investor demandThe proceeds will advance…